Medical Devices Europe

Europe Benign Prostatic Hyperplasia Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Europe Benign Prostatic Hyperplasia Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $2.38 Bn Placeholder estimate
Estimate 2025 $2.49 Bn 18.4% of the global market
Projected 2034 $3.66 Bn 47.3% Adds $1.18 Bn over 9 forecast years
CAGR 2025–2034 4.4% Faster than 9% of 173 Medical Devices markets here
Key players 5
  • Europe is 18.44% of the global market.
  • Among regions, the largest is North America at $6.17 Bn.
  • Fastest growing: Africa at 7.7% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.18 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Benign Prostatic Hyperplasia Treatment Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $2.38 Bn — —
2025 (base) $2.49 Bn +$104.8 Mn —
2026 (forecast) $2.60 Bn +$109.4 Mn +4.4%
2027 (forecast) $2.71 Bn +$114.2 Mn +9%
2028 (forecast) $2.83 Bn +$119.2 Mn +13.8%
2029 (forecast) $2.95 Bn +$124.5 Mn +18.8%
2030 (forecast) $3.08 Bn +$130.0 Mn +24%
2031 (forecast) $3.22 Bn +$135.7 Mn +29.5%
2032 (forecast) $3.36 Bn +$141.7 Mn +35.2%
2033 (forecast) $3.51 Bn +$147.9 Mn +41.1%
2034 (forecast) $3.66 Bn +$154.4 Mn +47.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Benign Prostatic Hyperplasia Treatment Market Analysis at a glance
Market size, 2025$2.49 Bn placeholder estimate
Forecast, 2034$3.66 Bn placeholder estimate
Growth (CAGR), 2025–20344.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, setting and end user (see all)
Key playersBoston Scientific Corporation, Teleflex Inc, Olympus Corporation, Procept BioRobotics, Astellas Pharma Inc. (see all)
Regulator in EuropeEU MDRSource: European Commission, medical devices. Checked 14 Nov 2026.
Active clinical trials22 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Benign Prostatic Hyperplasia Treatment Market Analysis Executive Summary

Benign prostatic hyperplasia treatments ease urinary problems from an enlarged prostate with medicines and minimally invasive procedures.

Key segments of the benign Prostatic Hyperplasia Treatment market include treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors and Prostatic Urethral Lift) and setting (Hospitals, Urology Clinics and Ambulatory Surgery Centers).

Bar chart: Europe Benign Prostatic Hyperplasia Treatment market size, 2024–2034, placeholder estimates. $2.38 Bn in 2024, $2.49 Bn in 2025 and $3.66 Bn in 2034, 4.4% CAGR.
Europe Benign Prostatic Hyperplasia Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Benign Prostatic Hyperplasia Treatment Market Dynamics

Market Growth Drivers

An ageing male population, more men seeking care, less invasive procedures and telehealth for sensitive conditions are driving the benign Prostatic Hyperplasia Treatment market.

Opportunity

Office-based procedures, direct-to-consumer telehealth and wider insurance coverage give the benign Prostatic Hyperplasia Treatment market room to grow.

Market Restraints

Stigma, out-of-pocket costs and limited reimbursement for some procedures hold back the benign Prostatic Hyperplasia Treatment market.

Competitive Landscape for Benign Prostatic Hyperplasia Treatment Market in Europe

The benign Prostatic Hyperplasia Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Benign Prostatic Hyperplasia Treatment Market in Europe

Benign Prostatic Hyperplasia Treatment in Europe: rules, payment and research

In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.⁠[1] In the countries we cover here, medical devices are regulated by ANSM (France)⁠[2], BfArM (Germany)⁠[3], Ministry of Health (Italy)⁠[4], Roszdravnadzor (Russia)⁠[5], AEMPS (Spain)⁠[6] and MHRA (UK)⁠[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[8] ClinicalTrials.gov lists 22 studies on Benign Prostatic Hyperplasia Treatment that are recruiting, active or about to start in Europe.⁠[9]

[1] European Commission, medical devices. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Ministry of Health. Checked 14 Nov 2026.

[5] Roszdravnadzor. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] European Commission, health technology assessment. Checked 14 Nov 2026.

[9] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how benign Prostatic Hyperplasia Treatment products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Benign Prostatic Hyperplasia Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Benign Prostatic Hyperplasia Treatment in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Benign Prostatic Hyperplasia Treatment market in Europe?
Placeholder estimate: about $2.49 Bn in 2025, rising to about $3.66 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Benign Prostatic Hyperplasia Treatment market in Europe growing?
Placeholder estimate: about 4.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Benign Prostatic Hyperplasia Treatment market report cover?
The report splits the market by treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, Prostatic Urethral Lift, Water Vapor Therapy and more), setting (Hospitals, Urology Clinics, Ambulatory Surgery Centers) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Benign Prostatic Hyperplasia Treatment market?
Key players include Boston Scientific Corporation, Teleflex Inc, Olympus Corporation, Procept BioRobotics and Astellas Pharma Inc..
What is driving the Benign Prostatic Hyperplasia Treatment market?
An ageing male population, more men seeking care, less invasive procedures and telehealth for sensitive conditions are driving the benign Prostatic Hyperplasia Treatment market.
Who regulates Benign Prostatic Hyperplasia Treatment in Europe?
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first. Source: European Commission, medical devices. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Benign Prostatic Hyperplasia Treatment are running in Europe?
22 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Benign Prostatic Hyperplasia Treatment?
PubMed lists 26 papers on Benign Prostatic Hyperplasia Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Europe

See all

Related on men's health and kidney health

See the topic